Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
PT Kalbe Farma Tbk. (KLBF.JK)
Jakarta, ID
PT Kalbe Farma Tbk., an Indonesian pharmaceutical leader, along with its subsidiaries, focuses on the development, manufacturing, and commercialization of pharmaceutical products across Indonesia. Its operations are structured into four primary divisions: Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribution & Logistics. The company's diverse portfolio encompasses generic, branded, and licensed medications, including well-known names like Brainact, Cefspan, and Mycoral, which are supplied to hospitals, pharmacies, and various drugstores. Beyond prescription drugs, it offers non-prescription medicines, a range of energy and ready-to-drink beverages, dietary supplements, and other preventive health solutions. Kalbe Farma also produces specialized nutritional products tailored for all demographics, from infants to seniors, including expectant mothers and individuals with specific medical dietary needs. The firm extends contract services to other pharmaceutical companies, covering clinical study management, bioavailability/bioequivalence assessments, and analytical testing. Additionally, it provides animal health products and operates its own healthcare facilities, the Mitrasana Clinics. Its broad scope of activities further includes health screening, acting as an agent for biotechnology products, and the distribution of consumer items, medical devices, and cosmetics. The company also trades in medical and laboratory equipment and supplies, raw materials for pharmaceuticals, and consumables for hemodialysis therapy, in addition to offering advertising services. Founded in 1966, PT Kalbe Farma Tbk. is headquartered in Jakarta, Indonesia.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.57% | -2.26% | -12.18% | -21.36% | -31.62% | -28.22% | -41.55% | -59.00% | -40.75% | -34.22% | +981.25% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 12 | 0 |
| Hold | 1 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - General: +6.6%+8.3% ★ Q1'26: +9.4% (vs Q1'25)
-
EPS growth Drug Manufacturers - General: +18.2%+14.8% Q1'26: -3.5% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%+10.6% Q1'26: +1.3% (vs Q1'25)
-
EBIT margin Drug Manufacturers - General: +19.4%+13.6% Q1'26: +13.5% (vs Q1'25)
-
ROIC Drug Manufacturers - General: +10.2%+18.4% ★ Q1'26: +19.0% (vs Q1'25)
-
Share dilution Drug Manufacturers - General: +0.0%-1.4% ★ Q1'26: -0.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×0.06× ★ Q1'26: 0.05× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 10 EPS Ana. |
Dec 2027 14 Rev. Ana. 13 EPS Ana. |
Dec 2028 7 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
17.89T
est: 17.90T (-0.1%)
|
19.37T
est: 19.58T (-1.1%)
|
20.18T
est: 20.49T (-1.5%)
|
21.07T
est: 21.13T (-0.3%)
|
22.63T
est: 22.65T (-0.1%)
|
23.11T
est: 23.50T (-1.6%)
|
26.26T
est: 25.88T (+1.5%)
|
28.93T
est: 29.00T (-0.2%)
|
30.45T
est: 31.60T (-3.6%)
|
32.63T
est: 32.66T (-0.1%)
|
35.32T
est: 35.10T (+0.7%)
|
38.04T
37.84T – 38.21T
+8.4% YoY
|
40.95T
38.48T – 42.69T
+7.6% YoY
|
44.01T
43.78T – 44.24T
+7.5% YoY
|
| EBITDA |
2.95T
est: 3.02T (-2.2%)
|
3.56T
est: 3.30T (+7.9%)
|
3.73T
est: 3.45T (+7.9%)
|
3.80T
est: 3.56T (+6.7%)
|
3.95T
est: 3.82T (+3.6%)
|
4.35T
est: 3.96T (+10.0%)
|
4.87T
est: 4.36T (+11.8%)
|
5.25T
est: 4.89T (+7.4%)
|
4.43T
est: 5.06T (-12.4%)
|
4.61T
est: 5.23T (-11.8%)
|
5.18T
est: 5.62T (-7.8%)
|
6.09T
6.06T – 6.12T
+8.4% YoY
|
6.56T
6.16T – 6.83T
+7.6% YoY
|
7.05T
7.01T – 7.08T
+7.5% YoY
|
| EBIT |
2.73T
est: 2.61T (+4.6%)
|
3.12T
est: 2.86T (+9.2%)
|
3.28T
est: 2.99T (+9.6%)
|
3.34T
est: 3.08T (+8.2%)
|
3.44T
est: 3.30T (+4.2%)
|
3.72T
est: 3.43T (+8.4%)
|
4.20T
est: 3.77T (+11.3%)
|
4.51T
est: 4.23T (+6.7%)
|
3.69T
est: 4.45T (-17.2%)
|
4.28T
est: 4.60T (-7.1%)
|
4.81T
est: 4.95T (-2.7%)
|
5.36T
5.33T – 5.39T
+8.4% YoY
|
5.77T
5.42T – 6.02T
+7.6% YoY
|
6.20T
6.17T – 6.24T
+7.5% YoY
|
| Net Income |
2.00T
est: 1.98T (+1.2%)
|
2.30T
est: 2.26T (+1.8%)
|
2.40T
est: 2.39T (+0.5%)
|
2.46T
est: 2.42T (+1.5%)
|
2.51T
est: 2.53T (-1.0%)
|
2.73T
est: 2.66T (+2.6%)
|
3.18T
est: 2.99T (+6.6%)
|
3.38T
est: 3.27T (+3.3%)
|
2.77T
est: 3.04T (-9.1%)
|
3.24T
est: 3.08T (+5.1%)
|
3.66T
est: 3.44T (+6.7%)
|
3.48T
3.21T – 3.75T
+1.3% YoY
|
3.82T
3.37T – 4.26T
+9.6% YoY
|
4.06T
3.62T – 4.51T
+6.5% YoY
|
| SGA |
3.12T
est: 2.59T (+20.5%)
|
3.53T
est: 2.84T (+24.5%)
|
3.51T
est: 2.97T (+18.1%)
|
3.46T
est: 3.06T (+13.1%)
|
3.60T
est: 3.28T (+9.8%)
|
3.35T
est: 3.40T (-1.6%)
|
3.86T
est: 3.75T (+3.0%)
|
4.05T
est: 4.20T (-3.5%)
|
4.45T
est: 4.63T (-4.0%)
|
4.76T
est: 4.79T (-0.6%)
|
5.45T
est: 5.15T (+5.8%)
|
5.58T
5.55T – 5.60T
+8.4% YoY
|
6.01T
5.64T – 6.26T
+7.6% YoY
|
6.45T
6.42T – 6.49T
+7.5% YoY
|
| EPS |
42.76
est: 42.87 (-0.3%)
|
49.06
est: 48.91 (+0.3%)
|
51.28
est: 51.78 (-1.0%)
|
52.42
est: 52.39 (+0.1%)
|
53.48
est: 54.83 (-2.5%)
|
58.31
est: 57.66 (+1.1%)
|
67.92
est: 64.69 (+5.0%)
|
72.71
est: 73.16 (-0.6%)
|
59.81
est: 65.89 (-9.2%)
|
70.16
est: 68.18 (+2.9%)
|
80.51
est: 75.93 (+6.0%)
|
79.13
70.50 – 82.43
+4.2% YoY
|
86.14
74.09 – 93.55
+8.9% YoY
|
90.29
79.57 – 99.01
+4.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 3/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-05 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-04 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-15 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bernadette Ruth Irawati Setiady | President Director | — | female |
| Maria Teresa Fabiola | Corporate Secretary | — | — |
| Rustam Tan | Head of Internal Audit Unit | — | male |
| Sie Djohan | Director of Corporate Business Development, Management System & Regulatory Affairs and Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for KLBF.JK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
